Equity Analysis /
United States of America

US : Immunovant, Inc. - IMVT | Ph 3 MG Trial Details; FDA Seemingly OK w/ Temporary LDL Elevations in Low-Risk Patients

    Danielle Brill
    CGS-CIMB
    5 January 2022
    Published by